BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 85] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
2 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
3 Luo M, Yan J, Wu L, Wu J, Chen Z, Jiang J, Chen Z, He B. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway. J Immunol Res 2021;2021:2264737. [PMID: 34458376 DOI: 10.1155/2021/2264737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 2019;18:416-21. [PMID: 31036494 DOI: 10.1016/j.aohep.2019.04.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
5 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
6 Kwong EK, Zhou H. Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. Liver Res 2019;3:19-24. [PMID: 31360579 DOI: 10.1016/j.livres.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wu LH, Chen MH, Cai JY, Yuan Y, Wu LQ, Zhou HM, Li L, Wan K, He XX. The correlation between intestinal mucosal lesions and hepatic dysfunction in patients without chronic liver disease. Medicine (Baltimore) 2020;99:e18837. [PMID: 32049785 DOI: 10.1097/MD.0000000000018837] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020; 26(16): 1901-1911 [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
9 Troisi J, Pierri L, Landolfi A, Marciano F, Bisogno A, Belmonte F, Palladino C, Guercio Nuzio S, Campiglia P, Vajro P. Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations. Nutrients 2017;9:E485. [PMID: 28492501 DOI: 10.3390/nu9050485] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
10 Croci S, D'Apolito LI, Gasperi V, Catani MV, Savini I. Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites. Nutrients 2021;13:1389. [PMID: 33919016 DOI: 10.3390/nu13051389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Dossett ML, Cohen EM, Cohen J. Integrative Medicine for Gastrointestinal Disease. Prim Care 2017;44:265-80. [PMID: 28501229 DOI: 10.1016/j.pop.2017.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
12 Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. J Agric Food Chem. 2019;67:2754-2762. [PMID: 30798598 DOI: 10.1021/acs.jafc.9b00080] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
13 Altamirano-barrera A, Uribe M, Chávez-tapia NC, Nuño-lámbarri N. The role of the gut microbiota in the pathology and prevention of liver disease. The Journal of Nutritional Biochemistry 2018;60:1-8. [DOI: 10.1016/j.jnutbio.2018.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
14 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 21.2] [Reference Citation Analysis]
15 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
16 Kim B, Kwon J, Kim MS, Park H, Ji Y, Holzapfel W, Hyun CK. Protective effects of Bacillus probiotics against high-fat diet-induced metabolic disorders in mice. PLoS One 2018;13:e0210120. [PMID: 30596786 DOI: 10.1371/journal.pone.0210120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
17 Dai X, Wang B. Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2015;2015:287348. [PMID: 25945084 DOI: 10.1155/2015/287348] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
18 Wang Y, Liang K, Kong W. Intestinal Trefoil Factor 3 Alleviates the Intestinal Barrier Function Through Reducing the Expression of TLR4 in Rats with Nonalcoholic Steatohepatitis. Arch Med Res. 2019;50:2-9. [PMID: 31101239 DOI: 10.1016/j.arcmed.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Cao GT, Dai B, Wang KL, Yan Y, Xu YL, Wang YX, Yang CM. Bacillus licheniformis, a potential probiotic, inhibits obesity by modulating colonic microflora in C57BL/6J mice model. J Appl Microbiol 2019;127:880-8. [PMID: 31211897 DOI: 10.1111/jam.14352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
20 Abd El-Hack ME, Samak DH, Noreldin AE, El-Naggar K, Abdo M. Probiotics and plant-derived compounds as eco-friendly agents to inhibit microbial toxins in poultry feed: a comprehensive review. Environ Sci Pollut Res Int 2018;25:31971-86. [PMID: 30229484 DOI: 10.1007/s11356-018-3197-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
21 Mohandas S, Soma VL, Tran TDB, Sodergren E, Ambooken T, Goldman DL, Weinstock G, Herold BC. Differences in Gut Microbiome in Hospitalized Immunocompetent vs. Immunocompromised Children, Including Those With Sickle Cell Disease. Front Pediatr 2020;8:583446. [PMID: 33282798 DOI: 10.3389/fped.2020.583446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Zhao Y, Zeng D, Wang H, Qing X, Sun N, Xin J, Luo M, Khalique A, Pan K, Shu G, Jing B, Ni X. Dietary Probiotic Bacillus licheniformis H2 Enhanced Growth Performance, Morphology of Small Intestine and Liver, and Antioxidant Capacity of Broiler Chickens Against Clostridium perfringens-Induced Subclinical Necrotic Enteritis. Probiotics Antimicrob Proteins 2020;12:883-95. [PMID: 31713770 DOI: 10.1007/s12602-019-09597-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
23 Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr 2021;10:100-2. [PMID: 33575294 DOI: 10.21037/hbsn.2020.03.27] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Seaman DR. Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors. J Chiropr Humanit 2016;23:68-76. [PMID: 27920621 DOI: 10.1016/j.echu.2016.07.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Zhao Y, Zhou J, Liu J, Wang Z, Chen M, Zhou S. Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease. Front Pediatr 2019;7:518. [PMID: 31921729 DOI: 10.3389/fped.2019.00518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
26 Birerdinc A, Younossi Z. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease? Journal of Hepatology 2015;62:761-2. [DOI: 10.1016/j.jhep.2015.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
27 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
28 Rashed ZE, Grasselli E, Khalifeh H, Canesi L, Demori I. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Med 2020. [PMID: 33142346 DOI: 10.1055/a-1273-3159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Braun HA, Faasse SA, Vos MB. Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. Gastroenterol Clin North Am 2018;47:949-68. [PMID: 30337043 DOI: 10.1016/j.gtc.2018.07.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
32 Nobili V, Putignani L, Mosca A, Chierico FD, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M, Drago L. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Arch Med Sci. 2018;14:81-87. [PMID: 29379536 DOI: 10.5114/aoms.2016.62150] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
33 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
34 Lira MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, de Oliveira Junior FA, de Almeida Filho ÉJB, Silva AS, Henrique da Costa-Silva J, de Brito Alves JL. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLoS One 2020;15:e0237360. [PMID: 32845887 DOI: 10.1371/journal.pone.0237360] [Reference Citation Analysis]
35 Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016;64:2015-27. [PMID: 27639192 DOI: 10.1002/hep.28829] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 31.3] [Reference Citation Analysis]
36 Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol 2016; 22(36): 8078-8093 [PMID: 27688650 DOI: 10.3748/wjg.v22.i36.8078] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 72] [Article Influence: 16.4] [Reference Citation Analysis]
37 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
38 Hsu TC, Huang CY, Liu CH, Hsu KC, Chen YH, Tzang BS. Lactobacillus paracasei GMNL-32, Lactobacillus reuteri GMNL-89 and L. reuteri GMNL-263 ameliorate hepatic injuries in lupus-prone mice. Br J Nutr 2017;117:1066-74. [PMID: 28502277 DOI: 10.1017/S0007114517001039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
39 Won SM, Park E, Jeong JJ, Ganesan R, Gupta H, Gebru YA, Sharma S, Kim DJ, Suk KT. The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. Int J Mol Sci 2021;22:8309. [PMID: 34361075 DOI: 10.3390/ijms22158309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018;102:1025-1036. [PMID: 29710519 DOI: 10.1016/j.biopha.2018.03.158] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
41 Abernathy BE, Schoenfuss TC, Bailey AS, Gallaher DD. Polylactose Exhibits Prebiotic Activity and Reduces Adiposity and Nonalcoholic Fatty Liver Disease in Rats Fed a High-Fat Diet. J Nutr 2021;151:352-60. [PMID: 33382431 DOI: 10.1093/jn/nxaa376] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Verduci E, Lassandro C, Radaelli G, Soldati L. Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach? J Transl Med 2015;13:109. [PMID: 25889212 DOI: 10.1186/s12967-015-0471-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Gao LL, Ma JM, Fan YN, Zhang YN, Ge R, Tao XJ, Zhang MW, Gao QH, Yang JJ. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol 2021;183:1379-92. [PMID: 33992651 DOI: 10.1016/j.ijbiomac.2021.05.066] [Reference Citation Analysis]
44 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
45 Kitabatake H, Tanaka N, Fujimori N, Komatsu M, Okubo A, Kakegawa K, Kimura T, Sugiura A, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Koinuma M, Sano K, Aoyama T, Tanaka E. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(4): 712-722 [PMID: 28216979 DOI: 10.3748/wjg.v23.i4.712] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
46 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 29.2] [Reference Citation Analysis]
47 Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis 2021;9:59-73. [PMID: 33332766 DOI: 10.1002/iid3.391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ji Y, Chung YM, Park S, Jeong D, Kim B, Holzapfel WH. Dose-dependent and strain-dependent anti-obesity effects of Lactobacillus sakei in a diet induced obese murine model. PeerJ 2019;7:e6651. [PMID: 30923658 DOI: 10.7717/peerj.6651] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
49 Kwon J, Kim B, Lee C, Joung H, Kim BK, Choi IS, Hyun CK. Comprehensive amelioration of high-fat diet-induced metabolic dysfunctions through activation of the PGC-1α pathway by probiotics treatment in mice. PLoS One 2020;15:e0228932. [PMID: 32040532 DOI: 10.1371/journal.pone.0228932] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
50 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 20.0] [Reference Citation Analysis]
51 Al-Muzafar HM, Amin KA. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. BMC Complement Altern Med 2017;17:43. [PMID: 28086768 DOI: 10.1186/s12906-016-1540-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
52 Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int 2021;15:350-65. [PMID: 33656663 DOI: 10.1007/s12072-021-10138-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 S Lavekar A, V Raje D, Manohar T, A Lavekar A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2017;7:130-7. [PMID: 29201794 DOI: 10.5005/jp-journals-10018-1233] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
54 Cao L, Quan XB, Zeng WJ, Yang XO, Wang MJ. Mechanism of Hepatocyte Apoptosis. J Cell Death. 2016;9:19-29. [PMID: 28058033 DOI: 10.4137/jcd.s39824] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 8.4] [Reference Citation Analysis]
55 Kim A, Krishnan A, Hamilton JP, Woreta TA. The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2021;50:217-41. [PMID: 33518166 DOI: 10.1016/j.gtc.2020.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Shen J, Zhang Z, Chen K, Lu M, Qian Q, Liu P, Gao Q, Zhang C. Prepregnancy obesity status and risks on pregnancy outcomes in Shanghai: A prospective cohort study. Medicine (Baltimore) 2018;97:e12670. [PMID: 30290653 DOI: 10.1097/MD.0000000000012670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
57 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
58 Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 2018;14:701-6. [PMID: 29765460 DOI: 10.5114/aoms.2016.58831] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
59 Okubo H, Kushiyama A, Nakatsu Y, Yamamotoya T, Matsunaga Y, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Asano T. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci 2018;19:E3064. [PMID: 30297626 DOI: 10.3390/ijms19103064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
60 Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, Zhang Y, Li Z, Wang B, Cao H. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier. Mol Pharm 2018;15:3860-70. [PMID: 30036479 DOI: 10.1021/acs.molpharmaceut.8b00347] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
61 Samadi N, Heiden D, Klems M, Salzmann M, Rohrhofer J, Weidmann E, Koidl L, Jensen-Jarolim E, Untersmayr E. Gastric Enzyme Supplementation Inhibits Food Allergy in a BALB/c Mouse Model. Nutrients 2021;13:738. [PMID: 33652629 DOI: 10.3390/nu13030738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 24.2] [Reference Citation Analysis]
63 李瑜元. 肠道微生态失调与非酒精性脂肪性肝病关系研究进展. 世界华人消化杂志 2015; 23(15): 2355-2362 [DOI: 10.11569/wcjd.v23.i15.2355] [Reference Citation Analysis]
64 Duarte SMB, Stefano JT, Vanni DS, Carrilho FJ, Oliveira CPMS. IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Arq Gastroenterol 2019;56:431-9. [PMID: 31721969 DOI: 10.1590/S0004-2803.201900000-67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
65 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
66 Zhang L, Xie Z, Yu H, Du H, Wang X, Cai J, Qiu Y, Chen R, Jiang X, Liu Z, Li Y, Chen T. TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells. Ann Transl Med 2021;9:1429. [PMID: 34733981 DOI: 10.21037/atm-21-4012] [Reference Citation Analysis]
67 Mularczyk M, Bourebaba Y, Kowalczuk A, Marycz K, Bourebaba L. Probiotics-rich emulsion improves insulin signalling in Palmitate/Oleate-challenged human hepatocarcinoma cells through the modulation of Fetuin-A/TLR4-JNK-NF-κB pathway. Biomed Pharmacother 2021;139:111560. [PMID: 33839491 DOI: 10.1016/j.biopha.2021.111560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Chen KL, Madak-erdogan Z. Estrogens and female liver health. Steroids 2018;133:38-43. [DOI: 10.1016/j.steroids.2017.10.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
69 Villanueva-Millán MJ, Pérez-Matute P, Oteo JA. Gut microbiota: a key player in health and disease. A review focused on obesity. J Physiol Biochem. 2015;71:509-525. [PMID: 25749935 DOI: 10.1007/s13105-015-0390-3] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 15.8] [Reference Citation Analysis]
70 Fontana L, Plaza-Díaz J, Robles-Bolívar P, Valente-Godínez H, Sáez-Lara MJ, Abadía-Molina F, Gómez-Llorented C, Gil Á, Álvarez-Mercado AI. Bifidobacterium breve CNCM I-4035, Lactobacillus paracasei CNCM I-4034 and Lactobacillus rhamnosus CNCM I-4036 Modulate Macrophage Gene Expression and Ameliorate Damage Markers in the Liver of Zucker-Lepr fa/fa Rats. Nutrients 2021;13:202. [PMID: 33440736 DOI: 10.3390/nu13010202] [Reference Citation Analysis]
71 张真玲, 段志军. 肠肝轴-肝病防治中的重要目标. 世界华人消化杂志 2016; 24(23): 3454-3460 [DOI: 10.11569/wcjd.v24.i23.3454] [Reference Citation Analysis]
72 Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 2020;11:882-99. [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
73 Nadeem Aslam M, Bassis CM, Zhang L, Zaidi S, Varani J, Bergin IL. Calcium Reduces Liver Injury in Mice on a High-Fat Diet: Alterations in Microbial and Bile Acid Profiles. PLoS One 2016;11:e0166178. [PMID: 27851786 DOI: 10.1371/journal.pone.0166178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
74 Sellmann C, Jin CJ, Degen C, De Bandt J, Bergheim I. Oral Glutamine Supplementation Protects Female Mice from Nonalcoholic Steatohepatitis. The Journal of Nutrition 2015;145:2280-6. [DOI: 10.3945/jn.115.215517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
75 Cogger VC, Mohamad M, Solon-Biet SM, Senior AM, Warren A, O'Reilly JN, Tung BT, Svistounov D, McMahon AC, Fraser R, Raubenheimer D, Holmes AJ, Simpson SJ, Le Couteur DG. Dietary macronutrients and the aging liver sinusoidal endothelial cell. Am J Physiol Heart Circ Physiol. 2016;310:H1064-H1070. [PMID: 26921440 DOI: 10.1152/ajpheart.00949.2015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
76 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
77 Strathearn LS, Stepanov AI, Font-Burgada J. Inflammation in Primary and Metastatic Liver Tumorigenesis-Under the Influence of Alcohol and High-Fat Diets. Nutrients 2020;12:E933. [PMID: 32230953 DOI: 10.3390/nu12040933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
78 Jiang J, Xiong J, Ni J, Chen C, Wang K. Live Combined B. subtilis and E. faecium Alleviate Liver Inflammation, Improve Intestinal Barrier Function, and Modulate Gut Microbiota in Mice with Non-Alcoholic Fatty Liver Disease. Med Sci Monit 2021;27:e931143. [PMID: 34482357 DOI: 10.12659/MSM.931143] [Reference Citation Analysis]
79 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
80 Xu Z, Lin S, Gong J, Feng P, Cao Y, Li Q, Jiang Y, You Y, Tong Y, Wang P. Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation. Front Med (Lausanne) 2021;8:681391. [PMID: 34179049 DOI: 10.3389/fmed.2021.681391] [Reference Citation Analysis]
81 Jeon MG, Kim TR, Lee JY, Kim HS, Ji Y, Holzapfel WH, Bae D, Choi CY, Hwang YP. Hepatoprotective Effects of Streptococcus thermophilus LM1012 in Mice Exposed to Air Pollutants. J Med Food 2020;23:852-61. [PMID: 32513044 DOI: 10.1089/jmf.2019.4636] [Reference Citation Analysis]
82 Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol 2018; 24(27): 2974-2983 [PMID: 30038464 DOI: 10.3748/wjg.v24.i27.2974] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 73] [Article Influence: 29.7] [Reference Citation Analysis]
83 de Campos Mazo DF, Mattar R, Stefano JT, da Silva-Etto JMK, Diniz MA, Duarte SMB, Rabelo F, Lima RVC, de Campos PB, Carrilho FJ, Oliveira CP. Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. World J Hepatol 2016; 8(24): 1019-1027 [PMID: 27648154 DOI: 10.4254/wjh.v8.i24.1019] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
84 Ning K, Lu K, Chen Q, Guo Z, Du X, Riaz F, Feng L, Fu Y, Yin C, Zhang F, Wu L, Li D. Epigallocatechin Gallate Protects Mice against Methionine-Choline-Deficient-Diet-Induced Nonalcoholic Steatohepatitis by Improving Gut Microbiota To Attenuate Hepatic Injury and Regulate Metabolism. ACS Omega 2020;5:20800-9. [PMID: 32875214 DOI: 10.1021/acsomega.0c01689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
85 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]